Search results
- 8.53Add to watchlist-0.32 (-3.62%)At close: Fri. Aug 16, 2024 4:00 PM EDT · Delayed Quote (USD) · Market closed
- Open9.00High9.10Low8.43
- Mkt Cap111.35MP/E (TTM)N/ADiv & YieldN/A & N/A
- Prev. Close8.8552 Wk. Low4.5352 Wk. High22.49
Related stocks
Find the latest Annovis Bio, Inc. (ANVS) stock quote, history, news and other vital information to help you with your stock trading and investing.
LEARN MORE ABOUT ANVS SCIENCE. Annovis Bio is developing a drug for Alzheimer's Disease, Parkinson's Disease and other neurodegenerative diseases that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport.
4 days ago · A high-level overview of Annovis Bio, Inc. (ANVS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
- www.marketwatch.com
- …
- Quotes
- Stocks
- United States
- ANVS
6 days ago · Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and...
4 days ago · Get a real-time Annovis Bio, Inc. (ANVS) stock price quote with breaking news, financials, statistics, charts and more.
Jul 15, 2024 · Discover real-time Annovis Bio, Inc. Common Stock (ANVS) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.
3 days ago · H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Annovis Bio (ANVS – Research Report) today and set a price target of $30.00. Ram Selvaraju has given his Buy rating due to a ...
5 days ago · Stock analysis for Annovis Bio Inc (ANVS:New York) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Jul 10, 2024 · Get real-time updates on Annovis Bio, Inc. Common Stock (ANVS) stock quotes, trades, and more. Make informed investments with Nasdaq.
Aug 6, 2024 · MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering ...